Relevant bibliographies by topics / Cetrorelix

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Cetrorelix'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cetrorelix.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cetrorelix"

1

Finch, Ann R., Christopher J. Caunt, Stephen P. Armstrong, and Craig A. McArdle. "Plasma Membrane Expression of Gonadotropin-Releasing Hormone Receptors: Regulation by Peptide and Nonpeptide Antagonists." Molecular Endocrinology 24, no. 2 (2010): 423–35. http://dx.doi.org/10.1210/me.2009-0343.

Full text
Abstract:
Abstract Gonadotropin-releasing hormone acts via cell surface receptors but most human (h) GnRH receptors (GnRHRs) are intracellular. A membrane-permeant nonpeptide antagonist [(2S)-2-[5-[2-(2-axabicyclo[2.2.2]oct-2-yl)-1,1-dimethy-2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine (IN3)] increases hGnRHR expression at the surface, apparently by facilitating its exit from the endoplasmic reticulum. Here we have quantified GnRHR by automated imaging in HeLa cells transduced with adenovirus expressing hemagglutinin-tagged GnRHR. Consistent with an intracellul
APA, Harvard, Vancouver, ISO, and other styles
2

Inani, Anita. "Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: A prospective case control study." Journal of Community Health Management 10, no. 4 (2024): 132–36. http://dx.doi.org/10.18231/j.jchm.2023.030.

Full text
Abstract:
Because of its terrible effects, ovarian hyperstimulation syndrome (OHSS) has long piqued the interest of medical professionals. Since the syndrome is an iatrogenic condition brought on by elective ovarian stimulation in the pursuit of pregnancy, its complete prevention is imperative. The gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has been shown in some studies to be beneficial in the prevention of OHSS as well as an effective treatment for the condition. Therefore, we created a study at a hospital to find out how Cetrorelix works to prevent and treat OHSS in patients undergoi
APA, Harvard, Vancouver, ISO, and other styles
3

V. Mishra, Vineet, Priyanka H. Rane, Rohina S. Aggarwal, Sumesh Choudhary, Manisha Chhetry, and Smit B. Solanki. "Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: a prospective case control study." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 12, no. 11 (2023): 3252–56. http://dx.doi.org/10.18203/2320-1770.ijrcog20233289.

Full text
Abstract:
Background: Ovarian hyperstimulation syndrome (OHSS) has intrigued clinicians for many years because of its devastating consequences. As an iatrogenic condition resulting from elective ovarian stimulation in the quest for pregnancy, the need to completely prevent the syndrome is evident. Gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has found to be effective in treatment of OHSS and some studies have found it to be helpful in prevention of this condition. Hence, we designed a hospital-based study to investigate the effect of Cetrorelix in preventing and treating OHSS in in-vitro
APA, Harvard, Vancouver, ISO, and other styles
4

Hussein, M., M. A. Alboghdady, A. S. Almorsy, et al. "Efficacy of gonadotropin-releasing hormone antagonists in the management of patients with severe early-onset ovarian hyperstimulation syndrome." Voprosy ginekologii, akušerstva i perinatologii 21, no. 6 (2023): 105–12. http://dx.doi.org/10.20953/1726-1678-2023-6-105-112.

Full text
Abstract:
Objective. To study the efficacy of gonadotropin-releasing hormone (GnRH) antagonists in the treatment of patients with severe early-onset ovarian hyperstimulation syndrome (OHSS). Patients and methods. This study including 60 women was conducted between January 2021 and January 2023 at Al-Azhar University Maternity Hospitals and private ART centers. Approval from the Research Ethics Committee was obtained to conduct the study. Patients were randomly divided into two groups: group I (n = 30; control group) received only standard therapy for severe OHSS, group II (n = 30; study group) received
APA, Harvard, Vancouver, ISO, and other styles
5

de Boer, Hans, Marian de Man, Kim de Bruyn, and Adriaan van Sorge. "Cetrorelix suppression test to assess the source of androgen overproduction in postmenopausal hirsutism." European Journal of Endocrinology 155, no. 3 (2006): 391–93. http://dx.doi.org/10.1530/eje.1.02224.

Full text
Abstract:
A 75-year-old woman presenting with recent onset hirsutism and severely elevated serum androgen levels was evaluated to assess the source of excessive androgen production. Commonly recommended hormonal stimulation and suppression tests, and the usually employed imaging techniques were non-diagnostic. In this report, we describe a new suppression test based on the use of the GnRH receptor antagonist, cetrorelix, to determine whether androgen production was LH-dependent. Cetrorelix, administered in a daily dose of 250 μg subcutaneously, suppressed serum LH within 24 h and reduced serum androgen
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Cetrorelix beneficial in BPH." Inpharma Weekly &NA;, no. 1167 (1998): 9. http://dx.doi.org/10.2165/00128413-199811670-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mohammadnejad, Daryosh, Faeze Daghigh, and Arezou Hamzehzadeh. "Chemotherapy-Related Structural Changes in Cancer: Effect of GnRH Antagonist in the Ovarian Follicles." International Journal of Women's Health and Reproduction Sciences 10, no. 4 (2022): 214–18. http://dx.doi.org/10.15296/ijwhr.2022.36.

Full text
Abstract:
Objectives: The adverse effect of chemotherapy on the proliferation of granulosa cells has been indicated in recent studies. Gonadotropin-releasing hormone (GnRH) antagonists exert protective effects on granulosa cells against the side effects of chemotherapy. In the present study, we aimed to evaluate the impact of cetrorelix on the proliferation of ovarian granulosa cells following administration of thiotepa in the ovaries of female mice. Materials and Methods: In this experimental study, 30 adult Balb/c female mice (5-8 weeks old, weighing 24-28 g) were divided into three groups (n=10/ each
APA, Harvard, Vancouver, ISO, and other styles
8

Firmawati, Aulia, Mitra Artha Kurnia Hutabarat, Herlina Pratiwi та Alibiruni Haryo. "Expression of estrogen receptors alpha (ERs α) and folliculogenesis profile in ovary of the rats ovarian hypofunction model". Jurnal Ilmu-Ilmu Peternakan 31, № 1 (2021): 18–26. http://dx.doi.org/10.21776/ub.jiip.2021.031.01.03.

Full text
Abstract:
Ovarian hypofunction is one of the reproductive disorders that occur due to a decrease in ovarian function that causes animals to not experience heat. The purpose of this study was to determine the effect of GnRH antagonist hormone interventions on ovarian hypofunction model rats by looking at the expression of alpha ERs (ERs α) and the profile of folliculogenesis in the ovaries. This study used two groups of female Wistar strain rats, aged 8-10 weeks, bodyweight 150-180 grams and each group contained 10 animals. Intervention gave control group, without cetrorelix acetate intervention (placebo
APA, Harvard, Vancouver, ISO, and other styles
9

Sperduti, Samantha, Silvia Limoncella, Clara Lazzaretti, et al. "GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors." International Journal of Molecular Sciences 20, no. 22 (2019): 5548. http://dx.doi.org/10.3390/ijms20225548.

Full text
Abstract:
Commercial gonadotropin-releasing hormone (GnRH) antagonists differ by 1–2 amino acids and are used to inhibit gonadotropin production during assisted reproduction technologies (ART). In this study, potencies of three GnRH antagonists, Cetrorelix, Ganirelix and Teverelix, in inhibiting GnRH-mediated intracellular signaling, were compared in vitro. GnRH receptor (GnRHR)-transfected HEK293 and neuroblastoma-derived SH-SY5Y cell lines, as well as mouse pituitary LβT2 cells endogenously expressing the murine GnRHR, were treated with GnRH in the presence or absence of the antagonist. We evaluated i
APA, Harvard, Vancouver, ISO, and other styles
10

Sommer, Lieselotte, Kerstin Zanger, Thomas Dyong, et al. "Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women." European Journal of Endocrinology 131, no. 3 (1994): 280–85. http://dx.doi.org/10.1530/eje.0.1310280.

Full text
Abstract:
Sommer L, Zanger K, Dyong T, Dorn C, Luckhaus J, Diedrich K, Klingmüller D. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol 1994;131:280–5. ISSN 0804–4643 In contrast to gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists do not show any stimulatory effect on the pituitary but their clinical usage was precluded by severe side effects and high dose requirements. We report here on a 7-day treatment using the potent GnRH antagonist Cetrorelix ([Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]GnRH) on
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cetrorelix"

1

Hempelt, Daniela. "Analytische Untersuchungen zur Aggregation von Cetrorelix und weiteren GnRH-Antagonisten." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2012. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-99807.

Full text
Abstract:
In der vorliegenden Arbeit werden Beiträge zur Entwicklung neuer qualitativer und quantitativer analytischer Methoden für die Untersuchung von Cetrorelix und anderen GnRH-Antagonisten während des Aggregationsprozesses vorgestellt. Für die qualitative Untersuchung von GnRH-Antagonisten wurden am Modellpeptid Cetrorelix massenspektrometrische Methoden entwickelt und auf weitere GnRH-Antagonisten übertragen. Eingesetzt wurde sowohl die ESI-TOF-MS als auch die MALDI-TOF-MS. Beide massenspektrometrische Verfahren zeigten für die untersuchten GnRH-Antagonisten polydisperse Verteilungen oberhalb der
APA, Harvard, Vancouver, ISO, and other styles
2

Rattei, Thomas. "Entwicklung und Charakterisierung von Komplexen aus Cetrorelix und biophilen Trägermaterialien." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2002. http://nbn-resolving.de/urn:nbn:de:swb:14-1029234929734-09131.

Full text
Abstract:
Die Dissertation beschreibt Arbeiten zur Herstellung neuer Cetrorelixkomplexe, zur Kinetik der dynamischen Liberation, zur Struktur von Aggregaten und Komplexen von Cetrorelix und zur Berechnung von Komplexeigenschaften mit Molecular Modeling<br>Presented are results about new complexes of cetrorelix, the kinetics of dynamical liberations, the structure of Cetrorelix aggregates and complexes and the computation of properties of complexes by molecular modeling
APA, Harvard, Vancouver, ISO, and other styles
3

Schäfer, Oliver. "Beeinflussung der peroralen Bioverfügbarkeit des Dekapeptids Cetrorelix, eines LHRH-Antagonisten, durch galenische Formulierungen /." [S.l. : s.n.], 1999. http://www.gbv.de/dms/bs/toc/302231056.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Krautmacher, Britta. "Effekte der Gonadotropin-releasing Hormon-Antagonisten Cetrorelix und Ganirelix auf IGF-II, IGFBP-2 und PAPP-A in humanen Granulosaluteinzellen." [S.l.] : [s.n.], 2004. http://deposit.ddb.de/cgi-bin/dokserv?idn=974508950.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hempelt, Daniela [Verfasser], Pée K. H. [Akademischer Betreuer] van, and Th [Akademischer Betreuer] Rattei. "Analytische Untersuchungen zur Aggregation von Cetrorelix und weiteren GnRH-Antagonisten / Daniela Hempelt. Gutachter: K.-H. van Pée ; Th. Rattei. Betreuer: K.-H. van Pée." Dresden : Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2012. http://d-nb.info/106844360X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schneider, Alexander. "Modellierung und Visualisierung von Systemen zur Beschreibung der intra- und intermolekularen Wechselwirkungen in hydrophoben Peptiden." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-155164.

Full text
Abstract:
Die vorliegende Arbeit beschäftigt sich mit der Untersuchung und Beschreibung der Eigenschaften der synthetischen Dekapeptide Cetrorelix und Ozarelix durch analytische Methoden und computergestützte Modellierung. Diese Moleküle sind hydrophobe, aggregierende Antagonisten des Gonadotropin-Releasing-Hormons (GnRH). Zusätzlich wurden amyloidbildende Peptidstrukturen als Modelle für die Assoziationsprozesse in hydrophoben Peptiden untersucht und visualisiert. Die intrinsische Fluoreszenz der GnRH-Antagonisten und zusätzlich der Peptide Teverelix und D-Phe6-GnRH sowie von verkürzten Fragmenten des
APA, Harvard, Vancouver, ISO, and other styles
7

Rattei, Thomas [Verfasser]. "Entwicklung und Charakterisierung von Komplexen aus Cetrorelix und biophilen Trägermaterialien / von Thomas Rattei." 2002. http://d-nb.info/966036565/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krautmacher, Britta [Verfasser]. "Effekte der Gonadotropin-releasing Hormon-Antagonisten Cetrorelix und Ganirelix auf IGF-II, IGFBP-2 und PAPP-A in humanen Granulosaluteinzellen / vorgelegt von Britta Krautmacher." 2004. http://d-nb.info/974508950/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cetrorelix"

1

Oltmanns, Kerstin. Wirkungen des Gonadotropin-Releasing Hormon-Antagonisten Cetrorelix auf die Steroidbiosynthese humaner Granulosaluteinzellen. 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cetrorelix"

1

"CETRORELIX." In Litt's Drug Eruptions and Reactions Manual. CRC Press, 2014. http://dx.doi.org/10.1201/b15347-42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"CETRORELIX." In Litt's Drug Eruption Reference Manual Including Drug Interactions. CRC Press, 2004. http://dx.doi.org/10.3109/9780203492079-36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Cetrorelix." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Furman, Brian L. "Cetrorelix." In xPharm: The Comprehensive Pharmacology Reference. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.61424-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Furman, B. L. "Cetrorelix ☆." In Reference Module in Biomedical Sciences. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-801238-3.98028-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cetrorelix"

1

Pratiwi, Herlina, Aulia Firmawati, Diana Rahmayani Putri, Albiruni Haryo, and Analis Wisnu Wardhana. "Interventions of Cetrorelix Acetate in Estrogen Beta Receptor Expression and Histopathology in Rats Oviduct." In 6th ICAMBBE (International Conference on Advance Molecular Bioscience & Biomedical Engineering) 2019. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009587300620067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seitz, S., AV Schally, A. Papadia, et al. "Effective tumor growth inhibition of MX1 and MDA-MB-231 estrogen receptor negative human breast cancer xenografts by treatment with LHRH antagonist cetrorelix." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Neumann, Brooke, Jerome Check, Carrie Wilson, Donna Summers, and Kathleen Hollahan. "Evaluation of Outcome Following Oocyte Retrieval in Women with Marked Diminished Oocyte Reserve (DOR) Where the Only Oocyte Retrieved Was in a Metaphase I State." In 27th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2023. https://doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.40_2023.

Full text
Abstract:
OBJECTIVE: To determine if there is value in culturing a metaphase I oocyte to metaphase II followed by intracytoplasmic sperm injection (ICSI), fertilization, then embryo transfer (ET) in women with marked DOR. MATERIALS AND METHODS: A follicle stimulating hormone (FSH) receptor up-regulation technique was used in women whose day 3 serum FSH levels were &gt;12 mIU/mL and/or the serum anti-mullerian (AMH) level was 1&lt;ng/mL to mature antral follicle(s) to the dominant follicle stage (average diameter &gt;18) and serum estradiol (E2) &gt;200pg/mL when 10,000 IU human chorionic gonadotropin (h
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cetrorelix' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography